Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
UPGRADE!!!!
MVP CAPITAL has just upgraded SPPI to a strong buy, $25 6 month target ...
Analyst MVP states "There are just too many big drugs in the pipeline to not take advantage of the current price of SPPI" and also warned shorts "The Boys are coming in to buy big blocks on Tuesday, and no, I'm not talking about the Dallas Cowboys"
He also believes that shorts should "bring a lot of Tums and Anti-Diarheal medication to work with them on Tuesday as explosions in the stock price of Spectrum could lead to explosions from the Rectum"
MVP also added that shorts should not "wear white pants in the morning" because when they leave work "they're probably going to be brown." He believes anyone short in SPPI should wear black and "prepare their brokerage account for its funeral".
Nice write up here by Street.com.
Doesn't say why the Earth stood still after the approval, lol, but a nice read anyway.
http://www.thestreet.com/story/10594701/1/spectrums-zevalin-okd-for-new-use.html
Well.....
I guess I'll say it, if nobody else will. Today was sure a major disappointment. Hard to say exactly why this price went down on an FDA approval. Heard different things from the Pr mix up as a price manipulation, to selling the news, because this approval was so expected, that this price was already baked in. Or that their accumulating shares because of a possible buy out soon. Anyone else think of anything?
That all be as it may, I'm still long here expecting an upgrade soon, I think it will only go up from here anyway.
Wow! Now that is really cold.
You picked a good day to do it. GLTY
NEPH
prnewswire
Nephros Awarded $2 Million Contract Expansion by the Office of Naval Research
http://finance.yahoo.com/news/Nephros-Awarded-2-Million-prnews-1264276276.html?x=0&.v=1
Spectrum Pharm volume and volatility elevated
BY Fly On The Wall
— 3:46 PM ET 08/31/2009
Spectrum Pharm, a commercial stage biopharmaceutical, is recently up 78c to $8.49. SPPI is presenting at the Rodman and Renshaw Annual Global Investment Conference on September 10. SPPI call option volume of 14,534 contracts compares to put volume of 3,195 contracts. SPPI September option implied volatility is at 173, October is at 150 and November is at 131; above its 26-week average of 109, according to Track Data, suggesting larger price movement.
Spectrum Pharm volume and volatility elevated
BY Fly On The Wall
— 3:46 PM ET 08/31/2009
Spectrum Pharm, a commercial stage biopharmaceutical, is recently up 78c to $8.49. SPPI is presenting at the Rodman and Renshaw Annual Global Investment Conference on September 10. SPPI call option volume of 14,534 contracts compares to put volume of 3,195 contracts. SPPI September option implied volatility is at 173, October is at 150 and November is at 131; above its 26-week average of 109, according to Track Data, suggesting larger price movement.
Spectrum Pharm volume and volatility elevated
BY Fly On The Wall
— 3:46 PM ET 08/31/2009
Spectrum Pharm, a commercial stage biopharmaceutical, is recently up 78c to $8.49. SPPI is presenting at the Rodman and Renshaw Annual Global Investment Conference on September 10. SPPI call option volume of 14,534 contracts compares to put volume of 3,195 contracts. SPPI September option implied volatility is at 173, October is at 150 and November is at 131; above its 26-week average of 109, according to Track Data, suggesting larger price movement.
Hang on tight!
Were rocking this morning!
No problem, just missed it, I understand.
Tanker AIG
Gapper SPPI
Everyone got their rally caps on today?
Looks like a nice green-shoot going into the weekend happening! :)
I got my sell stop in at 7.23 in case it breaks support from here.
Ya, with the run we've had the past few days, I figured we were due for some consolidation at some point. Looks now, at 10:21am to be finding some support around the 7.25 level, we'll see. I'm afraid if I got out now it would probably turn right back around, lol, so I'll just let it ride as the song goes, :)
Nice work D&D! I'm really surprised more IHUBer's aren't talking about SPPI.
It's gonna really be getting jiggy as we get closer to that first FDA approval date Sept 7th.
Hey Loniee! Check out SPPI!
Hot Bio-tech with and FDA approval pending Sept 7th.
SPPI Fundamentals:
1. Strong Cash Position to Continue to Execute on Business Plan with $106M in Cash, Equivalents, and Financing Receivable as of June 30, 2009
2. $8.1M in 2Q09 Revenue
3. 2Q09 ZEVALIN® Net Sales vs. 1Q09 ZEVALIN Net Sales Up 25%
4. Institutional Holdings - 37.7%
5. Short Interest As Of 7/31 - 12% of total float
6. 41.9M Shares Outstanding
7. FDA Decision on sBLA for ZEVALIN in First Line non-Hodgkin’s Lymphoma Expected by September 7th
8. FDA Decision on sNDA for FUSILEV™ in Metastatic Colorectal Cancer Expected by October 8th
9. * Strong Cash Position to Continue to Execute on Business Plan with $106M in Cash, Equivalents, and Financing Receivable as of June 30, 2009
10. On 8/6/09 SPPI announced they aquired full rights to RenaZorb, or SPI-014, which is a non-aluminum, non-polymer, non-calcium, lanthanum-based nanotechnology with highly potent and selective phosphate binding properties, for the potential treatment via oral administration, of hyperphosphatemia, (high phosphate levels in the blood), in patients with chronic kidney disease (CKD). Hyperphosphatemia in Stage 5 CKD, also known as end-stage renal disease (ESRD), can lead to significant bone disease (including pain and fractures), secondary hyperthyroidism in renal sufficiency, cardiovascular disease, and is independently associated with increased mortality. Currently marketed therapies for treating hyperphosphatemia include polymer-based and lanthanum-based phosphate binders, aluminum-based phosphate binders, and calcium-based phosphate binders. According to the United States Renal Data System (USRDS), over the last 20 years, the number of patients with ESRD in the US has grown 4-fold. By 2010 there will be an estimated 661,330 patients with ESRD.
11. The consensus held by most investors, analysts and commentators is that Zevalin will be approved as a first-line consolidation therapy for patients with NHL. It is important to note that Zevalin is already approved for use in the US for refractory NHL.
Institutional investors and hedge funds have been slow to catch on. With less than two weeks before FDA review, SPPI remains a hidden gem. With a current price of $7.52 and a market cap of only $263 million, SPPI is well positioned to hit new multi-year highs in the coming weeks with Zevalin’s approval. As always do your own DD, but this stock is poised to continue it's ascension. GLTA
Next week $ 10 !!!
I think that before September 7th SPPI will see $10.
$12.50-$15.00 after Zevalin gets approved.
I say we reach $18-23 if both approvals get done by Oct. 8th
Lol, I posted that on the Yahoo forums last night. I am s1ick1213. Look under your students, I am listed as s1ick. But the credit actually has to go to the maker of the Ibox for SPPI here at IHUB. Thats where I found the article.
Hows it looking to you? You still think its a go for approval on the 7th? If this thing runs to $10 before then its gonna be a tough decision on weather or not to hold through that date. But I'm loving it so far, watching my mustard seed grow, lol!
SPPI
This will continue to rise as the Sept 7th FDA approval date approaches.
SPPI Fundamentals:
1. Strong Cash Position to Continue to Execute on Business Plan with $106M in Cash, Equivalents, and Financing Receivable as of June 30, 2009
2. $8.1M in 2Q09 Revenue
3. 2Q09 ZEVALIN® Net Sales vs. 1Q09 ZEVALIN Net Sales Up 25%
4. Institutional Holdings - 37.7%
5. Short Interest As Of 7/31 - 12% of total float
6. 41.9M Shares Outstanding
7. FDA Decision on sBLA for ZEVALIN in First Line non-Hodgkin’s Lymphoma Expected by September 7th
8. FDA Decision on sNDA for FUSILEV™ in Metastatic Colorectal Cancer Expected by October 8th
9. * Strong Cash Position to Continue to Execute on Business Plan with $106M in Cash, Equivalents, and Financing Receivable as of June 30, 2009
10. On 8/6/09 SPPI announced they aquired full rights to RenaZorb, or SPI-014, which is a non-aluminum, non-polymer, non-calcium, lanthanum-based nanotechnology with highly potent and selective phosphate binding properties, for the potential treatment via oral administration, of hyperphosphatemia, (high phosphate levels in the blood), in patients with chronic kidney disease (CKD). Hyperphosphatemia in Stage 5 CKD, also known as end-stage renal disease (ESRD), can lead to significant bone disease (including pain and fractures), secondary hyperthyroidism in renal sufficiency, cardiovascular disease, and is independently associated with increased mortality. Currently marketed therapies for treating hyperphosphatemia include polymer-based and lanthanum-based phosphate binders, aluminum-based phosphate binders, and calcium-based phosphate binders. According to the United States Renal Data System (USRDS), over the last 20 years, the number of patients with ESRD in the US has grown 4-fold. By 2010 there will be an estimated 661,330 patients with ESRD.
11. The consensus held by most investors, analysts and commentators is that Zevalin will be approved as a first-line consolidation therapy for patients with NHL. It is important to note that Zevalin is already approved for use in the US for refractory NHL.
Institutional investors and hedge funds have been slow to catch on. With less than two weeks before FDA review, SPPI remains a hidden gem. With a current price of $7.52 and a market cap of only $263 million, SPPI is well positioned to hit new multi-year highs in the coming weeks with Zevalin’s approval. As always do your own DD, but this stock is poised to continue it's ascension. GLTA
SPPI Fundamentals:
1. Strong Cash Position to Continue to Execute on Business Plan with $106M in Cash, Equivalents, and Financing Receivable as of June 30, 2009
2. $8.1M in 2Q09 Revenue
3. 2Q09 ZEVALIN® Net Sales vs. 1Q09 ZEVALIN Net Sales Up 25%
4. Institutional Holdings - 37.7%
5. Short Interest As Of 7/31 - 12% of total float
6. 41.9M Shares Outstanding
7. FDA Decision on sBLA for ZEVALIN in First Line non-Hodgkin’s Lymphoma Expected by September 7th
8. FDA Decision on sNDA for FUSILEV™ in Metastatic Colorectal Cancer Expected by October 8th
9. * Strong Cash Position to Continue to Execute on Business Plan with $106M in Cash, Equivalents, and Financing Receivable as of June 30, 2009
10. On 8/6/09 SPPI announced they aquired full rights to RenaZorb, or SPI-014, which is a non-aluminum, non-polymer, non-calcium, lanthanum-based nanotechnology with highly potent and selective phosphate binding properties, for the potential treatment via oral administration, of hyperphosphatemia, (high phosphate levels in the blood), in patients with chronic kidney disease (CKD). Hyperphosphatemia in Stage 5 CKD, also known as end-stage renal disease (ESRD), can lead to significant bone disease (including pain and fractures), secondary hyperthyroidism in renal sufficiency, cardiovascular disease, and is independently associated with increased mortality. Currently marketed therapies for treating hyperphosphatemia include polymer-based and lanthanum-based phosphate binders, aluminum-based phosphate binders, and calcium-based phosphate binders. According to the United States Renal Data System (USRDS), over the last 20 years, the number of patients with ESRD in the US has grown 4-fold. By 2010 there will be an estimated 661,330 patients with ESRD.
11. The consensus held by most investors, analysts and commentators is that Zevalin will be approved as a first-line consolidation therapy for patients with NHL. It is important to note that Zevalin is already approved for use in the US for refractory NHL.
Institutional investors and hedge funds have been slow to catch on. With less than two weeks before FDA review, SPPI remains a hidden gem. With a current price of $7.52 and a market cap of only $263 million, SPPI is well positioned to hit new multi-year highs in the coming weeks with Zevalin’s approval. As always do your own DD, but this stock is poised to continue it's ascension. GLTA
SPPI- still running!
up to $7.47 now, weeee :)
$7.37 Now! WEEEEEEEEEE!
SPPI Gapping up in pm
FDA approval for Zevalin due Sept. 7th
http://seekingalpha.com/article/157299-spectrum-pharmaceuticals-the-labor-day-catalyst?source=email
TANKERS
Dow Jones
S&P 500
NASDAQ
There was definitely alot of institutional buying on the 13th and the 14th. Interesting to say the least. At least we know where the smart money is going. Although I am kinda surprised that the pps on Friday went down with all those institutions buying. I understand the market as a whole took a dump. Could there be some manipulation going on?
Still could be, you never know what it's gonna open at tomorrow
Could be a good short though
Nope your right. I guess I read the earnings wrong
I think we could play LEAP AH on the bounce
Wow sure took a dump
LEAP earnings through the roof!
I keep reading the results will be announced at the end of the 3rd quarter, does anyone know when that is?
8,988 at the close friday. I expect a pull back to some degree friday.
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Statistically Significant Results Reported from a Phase 2 Study Combining Two Oral Cancer Therapies
WAYNE, N.J. and EMERYVILLE, Calif., July 22 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that their first cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p = .0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
"Based on these encouraging data, Onyx and Bayer are evaluating various strategies for Nexavar in breast cancer. Nexavar is already benefiting patients worldwide with liver cancer and kidney cancer," said Todd Yancey, M.D., vice president of clinical development at Onyx. "Despite significant treatment advances, breast cancer continues to be the leading cause of cancer death in women.(i) We hope to establish Nexavar as an important new treatment option for patients with this devastating disease."
"This outcome represents a positive signal of the potential benefit of this combination for patients with advanced breast cancer and is the first statistical demonstration of efficacy for a multi-tyrosine kinase inhibitor in this disease," said Jose Baselga, M.D., chairman and professor of medicine at Vall d'Hebron Institute of Oncology in Barcelona and the principal investigator of this study. "One goal of this study was to evaluate the success of an all-oral regimen, which may represent a unique treatment option for patients with breast cancer."
Breast Cancer Trial Design
The randomized, double-blind, placebo-controlled Phase 2 study evaluated Nexavar in combination with the oral chemotherapeutic agent, capecitabine, in 229 patients. These patients had locally advanced or metastatic HER-2 negative breast cancer and had received no more than one prior chemotherapy in this setting. The primary endpoint of the study was progression-free survival. There were several secondary endpoints, including overall survival, time to progression, and safety. Patients were randomized to receive 400 mg of oral Nexavar or matching placebo twice daily, in addition to 1000 mg/m(2) of capecitabine twice daily for 14 days followed by a seven day rest from capecitabine.
About the Nexavar Clinical Program in Breast Cancer
Nexavar is being evaluated in collaboration with investigators and cooperative groups in a variety of treatment settings for patients with breast cancer. Among these trials are three ongoing randomized Phase 2 studies, including a trial to evaluate Nexavar plus paclitaxel in the first-line setting, a trial to evaluate Nexavar plus gemcitabine or capecitabine in the first- or second-line setting following progression on bevacizumab, and a trial to evaluate Nexavar plus docetaxel and/or letrozole in the first-line setting.
About Breast Cancer
Breast cancer was the most commonly diagnosed cancer among women worldwide in 2007-2008 (approximately 1.3 million cases), and the leading cause of death among women with cancer (approximately 465,000 deaths). It is the most commonly diagnosed cancer among women in the United States (1 in 4 cancer diagnoses is breast cancer). There are approximately 200,000 new cases of breast cancer in the U.S. and 350,000 in Europe each year. More than 40,000 women in the U.S. die of breast cancer each year.(i)
Nexavar's Differentiated Mechanism
Nexavar, an oral anti-cancer therapy, is currently approved in more than 70 countries for liver cancer and in more than 80 countries for the treatment of patients with advanced kidney cancer. Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.
Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including lung, ovarian and colorectal cancer and as an adjuvant therapy for liver and kidney cancer.
Important Safety Considerations For Patients Taking Nexavar
Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma and advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. In HCC patients, bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. In RCC patients, incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo. Most common adverse events greater than or equal to 20% related to Nexavar for both HCC and RCC were fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhea, nausea, and abdominal pain. Grade 3/4 adverse events in HCC and RCC patients, respectively, were 45% for Nexavar vs. 32% for placebo and 38% for Nexavar and 28% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.
For information about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).
About Bayer HealthCare Pharmaceuticals Inc.
I'm in at 10.50
Thanks for the trip down memory lane. I remember watching that match. I was dieing to see what Mascaras really looked like, Lol. That was back in the day when wrestlers were always getting bloody faces. The wrestling magazine covers always had bloody face on it, lol.